Daratumumab

Tax included
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.
MedChemExpress 
HY-P9915

Data sheet

Size
Multiple sizes
Reactivity
CD38; ADC Antibody
Application
COVID-19-immunoregulation
CAS
945721-28-8